LLS Publishes Free 'Know Your Subtype' Brochure
As they had been promising in email alerts, the Leukemia & Lymphoma Society has finally published a small but important free pamphlet entitled Know Your NHL Subtype.
The brochure is designed to be printed by the patient and brought to his or her next doctor's appointment so that the doctor can write down on the brochure the patient's accurate diagnosis, which includes the non-Hodgkin's lymphoma subtype.
The pamphlet includes some basic data and information regarding non-Hodgkin's lymphoma, including a shortlist out of the estimated 60 or more identified subtypes of the most commonly diagnosed NHL subtypes.
It lists indolent subtypes, including:
- Follicular lymphoma
- MALT lymphoma
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulenemia
- Cutaneous T-Cell Lymphoma
As well as aggressive subtypes, including
- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
- Burkitt's Lymphoma
- Anaplastic T-Cell Lymphoma
- Peripheral T-Cell Lymphoma
As the brochure notes, knowing your specific subtype can help you gain some control over the disease and therefore help you better cope with the diagnosis. It will also help you better understand the results of certain lab and imaging tests.
To see and print the brochure, click HERE (opens as a PDF file).
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
